MISTOSUS: a phase II trial of Viscum album extract adjuvant therapy for relapsed resectable osteosarcoma [0.03%]
英国临床肿瘤学会年会——米斯特索斯：艾叶提取物联合治疗复发性可切除骨肉瘤II期试验
Katharine Offer,Marcus Reif,Clark Andersen et al.
Katharine Offer et al.
Relapsed resectable osteosarcoma carries a dismal prognosis of 30% 12-month post-relapse event-free survival (PREFS-12). Surgery remains the primary therapy for metastatic pulmonary osteosarcoma with the role for adjuvant therapy still unde...
Precision palliative care in advanced/recurrent esophageal cancer patients treated with anti-PD-1/PD-L1 immunotherapy (ESO-Shanghai 25): a randomized, phase III Trial [0.03%]
精准肿瘤姑息治疗在抗PD-1/PD-L1免疫疗法的晚期/复发食管癌患者中的作用（ESO上海25）：一项随机III期临床试验
Shengnan Hao,Xiaomin Wang,Huiping Ding et al.
Shengnan Hao et al.
Over half of patients with advanced or recurrent esophageal cancer experience malnutrition, psychological distress, and cancer-related pain, which impair immune function, diminish quality of life, and attenuate responses to immunotherapy. W...
Beamion PANTUMOR-1: rationale and design of a Phase II trial of zongertinib in HER2-overexpressed/amplified or HER2-mutant solid tumors [0.03%]
ZEN-31019研究：泽美替尼治疗HER2高表达/扩增或突变的晚期实体瘤II期临床试验方案
Alison M Schram,John J Park,Antoine Italiano et al.
Alison M Schram et al.
Human epidermal growth factor receptor 2 (HER2, encoded by ERBB2) alterations are known oncogenic drivers in many solid tumors. Zongertinib is a novel, oral, irreversible, HER2-selective tyrosine kinase inhibitor that spares wild-type epide...
Odronextamab in people with relapsed or refractory follicular lymphoma: plain language summary of the ELM-2 study [0.03%]
ELM-2研究：奥德鲁奈马布治疗复发或难治性滤泡淋巴瘤的通俗版本总结报告
Jose C Villasboas,Michelle Poon,Monica Tani et al.
Jose C Villasboas et al.
Nivolumab plus chemotherapy in Asian people with advanced or recurrent stomach or gastroesophageal junction cancer (ATTRACTION-4 study): a plain language summary [0.03%]
纳武利尤单抗联合化疗治疗晚期或复发性胃癌或胃食管结合部癌（ATTraction-4研究）：简易概述
Li-Tzong Chen,Yoon-Koo Kang,Min-Hee Ryu et al.
Li-Tzong Chen et al.
Comparison of concurrent chemoradiotherapy followed by immunotherapy and induction chemoimmunotherapy followed by radiotherapy in unresectable stage III NSCLC: a retrospective cohort study [0.03%]
不可切除的III期非小细胞肺癌患者序贯放化疗联合免疫治疗和诱导化疗联合免疫治疗后放疗的对比研究：一项回顾性队列研究
Qinhao Xu,Yana Qi,Xiaoyang Zhai et al.
Qinhao Xu et al.
Background: Concurrent chemoradiotherapy followed by immune consolidation therapy (cCRT+IO, the PACIFIC regimen) is the standard treatment for unresectable stage III non-small cell lung cancer (NSCLC). However, the optima...
Operational efficiencies of using one vs multiple bispecific antibodies for diffuse large B-cell lymphoma and follicular lymphoma in the US [0.03%]
美国针对弥漫性大B细胞淋巴瘤和滤泡性淋巴瘤使用一种双特异性抗体与多种双特异性抗体的运营效率比较研究
Tara Graff,Savreet Bains Chawla,Monika Jun et al.
Tara Graff et al.
Aim: To quantify the time- and cost-savings to US oncology practices from using a single bispecific antibody (bsAb) for both relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) com...
Helping people navigate and make sense of cancer information: challenges and perspectives [0.03%]
协助人们了解和解读癌症相关信息：挑战与展望
Lisa Rezende,Gissoo DeCotiis,Eric K Singhi
Lisa Rezende
People living with cancer, and their caregivers and families, have access to many sources of health information. This brings both positives and challenges. Some information is not easy to understand and it can be difficult to know what is r...
Real-world outcomes after CAR T versus standard therapy in third-line or later relapsed or refractory follicular lymphoma in the United States [0.03%]
美国复发或难治性滤泡淋巴瘤三线或后线疗法CAR-T与标准疗法的现实世界疗效对比研究
Philip K Chan,Markqayne Ray,Karl M Kilgore et al.
Philip K Chan et al.
Background: Relapsed/refractory (R/R) follicular lymphoma (FL) often requires multiple lines of therapy. Objective: To compare time to ...